Poly Medicure Q1 FY27: 28% EBITDA, FY27 guidance intact

Key takeaway from the Q1 FY27 update

Poly Medicure (NSE: POLYMED) discussed its Q1 FY27 performance in an earnings call released on August 10, 2026, outlining a quarter where margins surprised on the upside even as costs rose. The company reported strong year-on-year revenue growth at both standalone and consolidated levels, supported by acquisitions and organic expansion. Management also reiterated its full-year FY27 revenue guidance for both consolidated and standalone operations. The quarter stood out for a sharp improvement in gross margins, helped by product mix, price increases, and inventory gains. At the same time, the call highlighted pressure pockets, especially in the renal segment due to pricing intensity.

When the results were discussed

The company had a board meeting scheduled for August 7, 2026 to approve unaudited Q1 FY27 standalone and consolidated results, as per the provided details. An earnings conference call was scheduled for August 10, 2026 from 4:00 PM to 5:00 PM IST, with the intimation filed on August 5, 2026. The transcript excerpt also indicates the call timing as Aug 10, 2026 / 10:30 AM GMT. Management participants named in the call details included Himanshu Baid (Managing Director) and Rahul Gautam (President, Strategy and Corporate Development), along with Naresh Vijayvergiya.

Standalone performance: revenue up 12.3%, gross margin at 71.5%

Management reported standalone revenue of INR 431 crore in Q1 FY27, up 12.3% year-on-year. Within this, domestic revenue was cited at INR 146 crore, with domestic growth of 16.2%. International revenue was stated at INR 281.8 crore, with international growth of 10% on a standalone basis. Standalone gross margin improved to 71.5%, which management attributed to a better product mix, price hikes, and inventory gains. The company also flagged that standalone gross margins are expected to normalize to 68%-69% in the near term.

Consolidated performance: acquisitions lift reported growth

On a consolidated basis, Q1 FY27 revenue was reported at INR 525 crore to INR 525.4 crore, up 30.3% year-on-year from INR 403.2 crore. Management cited organic growth of 12.4% within that consolidated growth number. The quick summary also noted INR 72.3 crore of revenue contribution from acquisitions in the quarter. Consolidated gross margin improved to 73.4%, up 495 basis points year-on-year, with the benefit attributed to higher-margin acquired businesses.

EBITDA: standalone beats guidance while consolidated stays in band

Standalone EBITDA margin was reported at 28% in Q1 FY27, above management’s guided range of 25%-27%. Management specifically pointed to this as an EBITDA beat, even as employee costs rose 29% year-on-year on the standalone base. Consolidated EBITDA margin was stated at 24.1%, which sits within the company’s guided 23%-25% range for FY27. One section of the provided text also quantified consolidated EBITDA at INR 125 crore versus INR 105.7 crore a year earlier, with EBITDA up 18.3% year-on-year. Another excerpt attributed consolidated margin pressure to integration costs from acquisitions and a sharp rise in employee benefit expenses, cited at 70.6% year-on-year.

Profit and EPS: what was stated in the provided text

The provided information said profit fell 8.4% year-on-year to INR 85 crore in Q1 FY27 from INR 93 crore. A separate line stated consolidated PAT declined 8.4% to INR 85.3 crore. Another portion of the text mentioned consolidated net profit of INR 86 crore as “reportedly” indicated by a source alert and not independently verified against regulatory filings, advising readers to treat it as preliminary until filings are available. The text also stated the company posted earnings of 7.00 per share on revenue of INR 535 crore, ahead of forecasts of 6.78 per share and INR 521 crore in sales.

Geographic and segment signals: Europe recovery, renal pressure

Europe was highlighted as a region showing strong recovery, with 43.8% reported growth and 17.6% organic growth, supported by new customer additions and improved performance. The renal segment was described as weak, with growth of 3.8%, attributed to pricing pressure from Chinese players and a cautious approach to volumes. Management also said domestic infusion therapy grew over 20% in Q1, with cardiology and critical care contributing meaningfully.

Cardiology scaling: jump from INR 2.9 crore to INR 28.6 crore

A notable operating detail from the quarter was the cardiology segment scaling up sharply from INR 2.9 crore to INR 28.6 crore. The call notes linked this jump to acquisitions and domestic expansion. This is consistent with the broader theme in the quarter that acquired businesses are influencing the consolidated growth profile and margin mix.

Balance sheet and cash position

Management said the company maintained a strong balance sheet with INR 855 crore in cash. The call noted that this cash is earmarked for strategic initiatives and expansion. While no further breakdown was provided in the supplied material, the cash figure was positioned as supporting the company’s next phase of growth initiatives.

Guidance: FY27 targets reiterated

Poly Medicure reiterated consolidated revenue guidance of INR 2,300-2,400 crore for FY27, including full-year consolidation of acquired entities referenced as Pendragon and CTFE in the quick summary. It also maintained standalone revenue guidance of INR 1,900-2,000 crore, with domestic growth targeted at more than 20% and international growth at more than 15%. On margins, the company guided standalone EBITDA margin at 25%-27% and consolidated EBITDA margin at 23%-25%, with management commentary pointing to standalone margins trending toward the upper end.

Key numbers snapshot (as stated)

Market impact: what the quarter changes for investors

The quarter reinforced that Poly Medicure’s reported consolidated growth rate is being lifted by acquisitions, with INR 72.3 crore of quarterly revenue attributed to acquired businesses in the summary. At the same time, management’s expectation that standalone gross margins normalize to 68%-69% sets a near-term reference point after the 71.5% standalone gross margin print. The EBITDA outcome was mixed across reporting lines: standalone margins exceeded the guided band, while consolidated margins stayed within guidance despite integration and employee benefit cost pressures mentioned in the text. Segment-level disclosures showed divergent conditions, with cardiology scaling quickly while renal faced pricing pressure from Chinese competitors. For investors tracking execution risk, the call framed integration costs and higher employee expenses as current factors alongside margin support from higher-margin acquired businesses.

Analysis: why the margin beat and guidance matters

Two operational levers were explicitly linked to margin strength in the quarter: product mix improvement and pricing actions, with inventory gains also contributing to the standalone gross margin. The magnitude of the standalone EBITDA margin at 28% matters because it came despite a stated 29% rise in employee costs, indicating operating leverage and mix effects in the quarter. On the consolidated side, the margin staying within the guided 23%-25% band is consistent with management’s stance that acquired businesses are contributing positively to gross margin, even as integration and staffing costs weigh on EBITDA margin comparisons. The guidance reiteration for FY27 consolidated revenue at INR 2,300-2,400 crore and standalone revenue at INR 1,900-2,000 crore gives a clear planning anchor for the year, especially in a quarter where growth quality differed across segments and geographies.

Conclusion

Poly Medicure’s Q1 FY27 update combined strong top-line growth with a standalone EBITDA margin outcome that exceeded the company’s stated guidance range. Consolidated performance reflected acquisition-led uplift, while management maintained FY27 revenue and margin guidance bands. Near-term attention points from the call include the expected normalization of standalone gross margins to 68%-69% and the ongoing cost and integration dynamics tied to recent acquisitions. The next confirmations for investors will come through the company’s formal filings and subsequent quarterly updates against the reiterated FY27 targets.